The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

In 2022, the global monoclonal antibodies market size was valued at USD 186 billion in 2021. The market is projected to ...

Truist lowered the firm’s price target on Regeneron (REGN) to $1,137 from $1,200 and keeps a Buy rating on the shares after ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

The long-term risk of distant recurrence for women with early breast cancer has declined significantly, a decades-long ...